Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety

NCT07221877 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07221877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 4
Overall status
Recruiting
Start date
January 20, 2026
Completion date
December 30, 2027
Enrollment
60 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia